REGN Q4 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.9B+2.5% YoY

Gross Profit

$3.3B84.9% margin

Operating Income

$880M22.7% margin

Net Income

$845M21.7% margin

EPS (Diluted)

$7.86

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$922M

Stock-Based Comp.

$249M

Balance Sheet

Total Assets

$40.6B

Total Liabilities

$9.3B

Stockholders' Equity

$31.3B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$3.8B	+2.5%
Gross Profit	$3.3B	$3.2B	+2.4%
Operating Income	$880M	$990M	-11.1%
Net Income	$845M	$918M	-8.0%

Revenue Segments

Collaboration Revenue

$2.0B51%

Product

$1.7B43%

Product and Service, Other

$239M6%

Geographic Segments

UNITED STATES

$3.3B90%

Rest Of World

$361M10%